Feasibility trial reports deployment of new device for TAVI in aortic insufficiency

May 24, 2013

A new investigational device - the Helio System (TF-FA) - being developed for use with the Sapien XT Transcatheter Heart Valve was successfully deployed in all four patients in a small, first-in-human feasibility study of its use in high-risk aortic insufficiency reported at EuroPCR 2013.

The HELIO dock system acts as an anchor to help stabilise the SAPIEN XT valve for with aortic insufficiency. The native leaflets in the heart are captured between the transcatheter heart valve and the dock. "This is an innovative, minimally to treat aortic insufficiency," said the lead author of the study, Sanjeevan Pasupati, specialist in coronary and structural heart disease intervention, Waikato Hospital, Hamilton, New Zealand. He explained that currently available valves anchor to calcified valves. "What makes aortic insufficiency different from aortic stenosis – for which transcatheter aortic valve implantation (TAVI) is established – is the lack of calcium in the aortic leaflets and annulus, making it challenging to anchor the transcatheter heart valve. We need a system to anchor the valve in these patients."

The prospective trial using the transfemoral or transapical approach was designed as a clinical evaluation of the safety and initial performance of the new system in high-risk aortic insufficiency. Four patients (mean age 70+10 years) were recruited at Dr Pasupati's centre between August 2011 and June 2012. Their mean logistic EuroSCORE was 8.6+1.3 and mean left was 57%+16%. The mean native annulus diameter was 25.4+1.1mm and the mean gradient was 20.1+8.8mmHg. They were followed-up at and at 30 days, six months and 12 months and will continue to be followed-up annually out to five years.

Pasupati reported that there were no in-hospital deaths. One patient had a stroke/TIA and one suffered minor vascular complication. One patient, who had pre-existing , had an acute kidney injury. "The primary endpoint of freedom from all-cause mortality at 30 days was 100%," he told the conference, adding that all four patients were alive at one year. He added, "Successful delivery and deployment of the HELIO System and retrieval of the delivery systems resulting in improved aortic insufficiency in the earliest evaluable echocardiogram post-implant was achieved in all four patients." Aortic insufficiency improved from moderate to severe before the procedure to trivial at 30 days. Two patients followed up at 12 months had no aortic insufficiency at this time point.

Commenting on the implications of the study findings, Professor Stephan Windecker, Professor and Chief of Cardiology, Swiss Cardiovascular Center and Clinical Trials Unit Bern, Bern University Hospital, Switzerland, said, "The field of transcutaneous implantation is expanding in indications from its well established use in aortic stenosis to other causes of aortic regurgitation. The larger annulus size in patients with aortic insufficiency without stenosis means we need facilitating techniques to use devices previously used in aortic stenosis. In this study it is encouraging to treat patients with aortic regurgitation for which we have not previously had suitable devices."

Explore further: MDCT helps better determine valve implant size for transcatheter aortic valve in patients with aortic stenosis

Related Stories

MDCT helps better determine valve implant size for transcatheter aortic valve in patients with aortic stenosis

April 13, 2013
MDCT is a better way to measure annular size in patients with aortic stenosis who are candidates for transcatheter aortic valve implantation (TAVI) than two dimensional echocardiography, a new study indicates.

Second-generation TAVI device—Lotus Valve—shows good performance in REPRISE II

May 23, 2013
22 May 2013, Paris, France: The Lotus Valve, a second-generation transcatheter aortic valve implantation (TAVI) device, was successfully implanted in all of the first 60 patients in results from REPRISE II reported at EuroPCR ...

Post-approval TAVI registry shows high rates of device success at one year

May 21, 2013
One-year results from SOURCE XT – one of the largest, post-approval transcatheter aortic valve implantation (TAVI) registries to-date – reported today at EuroPCR 2013 show good clinical outcomes in routine clinical practice, ...

Transcatheter aortic valve implantation shows promise in patients with severe aortic stenosis

April 10, 2012
German researchers report success with transcatheter aortic valve implantation (TAVI) in patients with low-flow, low-gradient aortic stenosis—a special form of aortic stenosis that is difficult to treat. Results published ...

Study confirms benefits of transcatheter aortic valve replacement over 3 years

October 24, 2012
A study found that transcatheter aortic valve replacement (TAVR) yielded lower mortality rates after three years compared with medical therapy in patients deemed to be ineligible for conventional aortic valve surgery. Results ...

Minimally-invasive failed biological aortic valve replacement successful in high risk patients

May 6, 2013
When a biologic aortic valve prosthesis fails, the patient often faces a high risk valve replacement through repeat open heart surgery. A new technique, known as Valve-in-Valve, uses minimally invasive techniques to introduce ...

Recommended for you

Could aggressive blood pressure treatments lead to kidney damage?

July 18, 2017
Aggressive combination treatments for high blood pressure that are intended to protect the kidneys may actually be damaging the organs, new research from the University of Virginia School of Medicine suggests.

Quantifying effectiveness of treatment for irregular heartbeat

July 17, 2017
In a small proof-of-concept study, researchers at Johns Hopkins report a complex mathematical method to measure electrical communications within the heart can successfully predict the effectiveness of catheter ablation, the ...

Concerns over side effects of statins stopping stroke survivors taking medication

July 17, 2017
Negative media coverage of the side effects associated with taking statins, and patients' own experiences of taking the drugs, are among the reasons cited by stroke survivors and their carers for stopping taking potentially ...

Study discovers anticoagulant drugs are being prescribed against safety advice

July 17, 2017
A study by researchers at the University of Birmingham has shown that GPs are prescribing anticoagulants to patients with an irregular heartbeat against official safety advice.

Protein may protect against heart attack

July 14, 2017
DDK3 could be used as a new therapy to stop the build-up of fatty material inside the arteries

Heart study finds faulty link between biomarkers and clinical outcomes

July 14, 2017
Surrogate endpoints (biomarkers), which are routinely used in clinical research to test new drugs, should not be trusted as the ultimate measure to approve new health interventions in cardiovascular medicine, according to ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.